BEY1107

Phase 2Small molecule

BBeyondBio Inc.

BEY1107 is one of 134 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

133

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerRecruiting

Pancreatic CancerRecruiting

Glioblastoma MultiformeRecruiting

Metastatic Colorectal CancerPhase 2

Recruiting

Pancreatic CancerPhase 2

Recruiting

Glioblastoma MultiformePhase 1

Recruiting

Competition

Competitive Landscape

307 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Medrol

Pfizer

Preclinical

1 2

Byetta

AstraZeneca

Preclinical

1 3

BEY1107

BBeyondBio Inc.

Phase 2

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 5

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 6

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Active Comparator

Moderna

Preclinical

1 9

Secretin-Ferring

Ferring

Preclinical

1 10

Sulfonylureas

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Metastatic Colorectal Cancer

NCT05093907

Phase 1/2Recruiting

Pancreatic Cancer

NCT03579836

Phase 1Recruiting

Glioblastoma Multiforme

NCT05769660

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer

Recruiting·BBeyondBio Inc.·Phase 1/2·NCT05093907·27 enrolled

Pancreatic Cancer1 trial

Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer

Recruiting·BBeyondBio Inc.·Phase 1/2·NCT03579836·75 enrolled

Glioblastoma Multiforme1 trial

A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)

Recruiting·BBeyondBio Inc.·Phase 1·NCT05769660·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BEY1107. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BEY1107 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BEY1107. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BeyondBio Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBeyondBio Inc.

BEY1107

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

Pancreatic Cancer1 trial

Glioblastoma Multiforme1 trial

References

Drug Info

Quick Facts

Related News